Lonza reported strong H1 2026 sales and margin growth
The company upgraded its full-year margin outlook and saw double-digit growth across all platforms.
See the latest news and media coverage for Lonza. We track all announcements, press releases, and industry mentions in real time, all in one place.
Dedicated CDMO serving the healthcare industry
lonza.comLast updated
In short: Lonza reported strong H1 2026 sales of 3.4 billion francs and upgraded its margin outlook after completing its pivot to a pure-play CDMO.
The company upgraded its full-year margin outlook and saw double-digit growth across all platforms.
Expanded collaboration aims to develop next-generation brain delivery solutions for CNS diseases.
The expansion adds commercial-scale HPAPI capacity for complex payload-linkers and is expected operational in 2028.
The restatement reflects Capsules & Health Ingredients as discontinued operations, aligned with Full-Year 2025 reporting.
The pharmaceutical manufacturer Lonza sees itself at an advantage thanks to its international production network. In the new large plant in California, it still has free capacity.
Swiss contract development and manufacturing group Lonza today reported sales of 3.4 billion francs ($4.25 billion) in the ...
The shares of the pharmaceutical contract manufacturer Lonza were passed to the bottom of the SMI table on Wednesday after the half-year figures. Will they now make a rebound?
, opens new tab, the world's largest contract drug manufacturer, raised its margin goal but stuck...
Track Lonza and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lonza and other trending companies.